Cell Therapeutics Inc

Entity type image
Type: Company
Name: Cell Therapeutics Inc
First reported May 24 2013 - Updated May 24 2013 - 1 reports

Form 4 CELL THERAPEUTICS INC For: May 24 Filed by: LOVE RICHARD L

StreetInsider.com - Form 4 CELL THERAPEUTICS INC For: May 24 Filed by: LOVE RICHARD L ... [Published Street Insider - May 24 2013]
First reported May 22 2013 - Updated May 23 2013 - 2 reports
US Securities and Exchange Commission
US Securities and Exchange Commission

Cell Therapeutics Inc. Files SEC Form DEF 14A, Other Definit. . .

Cell Therapeutics Inc. Files SEC Form DEF 14A, Other Definitive Proxy Statements (May. 13, 2013)Pharmaceutical PreparationsNewsRx.comBy a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, ... [Published Equities.com - May 22 2013]
First reported May 22 2013 - Updated May 22 2013 - 1 reports

Investors look to Lighten Up on Shares of Cell Therapeutics, Shares Down 5.2% (CTIC)

(Comtex SmarTrend(R)) Cell Therapeutics (NASDAQ:CTIC) is one of today's worst performing low-priced stocks, down 5.2% to $1.25 on 1.8x average daily volume. Thus far today, Cell Therapeutics has traded 1.1 million shares, vs. average volume of 643,000 ... [Published Individual.com - May 22 2013]
First reported May 22 2013 - Updated May 22 2013 - 1 reports

Cell Therapeutics, Inc. Presents at UBS Global Healthcare Conference, May-21-2013 02:30 PM

Unknown AnalystSo I'm [indiscernible]. I cover biotech space in Europe for UBS. I just would like to introduce Dr. Blanco, CEO for CTI. So you can have probably a 25 minutes presentation.James A. BiancoThank you. Good afternoon. As is typical of the presentations ... [Published Seeking Alpha - May 22 2013]
First reported May 21 2013 - Updated May 21 2013 - 1 reports

Cell Therapeutics receives German Federal Joint Committee's final benefit assessment report for Pixuvri

Cell Therapeutics, Inc. (CTI), a biopharmaceutical company, announced that Germany's Federal Joint Committee (G-BA) has issued its final benefit assessment report for Pixuvri (pixantrone), which is indicated as a monotherapy for the treatment of adult ... [Published PharmaBiz - May 21 2013]
First reported May 20 2013 - Updated May 20 2013 - 1 reports

Germany’s G-BA Finds No Added Benefit For CTI’s Pixuvri, Exposing Price

Germany’s G-BA lets through Cell Therapeutics’ Pixuvri for aggressive B-cell non-Hodgkin's lymphoma but finds no added benefit over existing therapies, meaning its price could come under pressure. ... [Published The Rose Sheet - May 20 2013]
First reported May 20 2013 - Updated May 20 2013 - 1 reports

German Federal Joint Committee (G-BA) Issues Final Assessment Report for PIXUVRI® (pixantrone)

CELL THERAPEUTICS INC Symbol U : CTIC Recent Sedar Documents German Federal Joint Committee (G-BA) Issues Final Assessment Report for PIXUVRI® (pixantrone) ... [Published Stockwatch - May 20 2013]
Entities: pixantrone, Pixuvri, Federal
First reported May 16 2013 - Updated May 16 2013 - 1 reports

Cell Therapeutics reports higher Q1 net loss, provides outlook for 2013

Cell Therapeutics, Inc., a biopharmaceutical company, has reported that net loss for the first quarter ended March 31, 2013 was $19.38 million, or $0.18 loss per share, compared to a net loss of $17.45 million, or $0.43 loss per share, for the same quarter ... [Published Individual.com - May 16 2013]
First reported May 15 2013 - Updated May 15 2013 - 3 reports

Cell Therapeutics, Inc. to Present at Upcoming Investor Conferences

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!SEATTLE , May 15, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced... ... [Published BioSpace - May 15 2013]
First reported May 11 2013 - Updated May 11 2013 - 2 reports

Form 4 CELL THERAPEUTICS INC For: May 09 Filed by: BIANCO LOUIS A

StreetInsider.com - Form 4 CELL THERAPEUTICS INC For: May 09 Filed by: BIANCO LOUIS A ... [Published Street Insider - May 11 2013]
First reported May 03 2013 - Updated May 03 2013 - 1 reports

Cell Therapeutics, Inc. Reports First Quarter 2013 Financial Results

/PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported financial results for the first quarter ended March 31, 2013. "In the first quarter, we generated initial commercial sales of PIXUVRI® in countries in the European Union ... [Published BioSpace - May 03 2013]
First reported May 02 2013 - Updated May 02 2013 - 1 reports

Cell Therapeutics' loss widens as it begins selling cancer drug

Cell Therapeutics Inc. generated $1.1 million revenues through European sales of its cancer drug Pixuvri, but still posted a $19.4 million loss for the first quarter of 2013.That’s more than the $17.4 million loss for the first quarter of 2012.As of March ... [Published Puget Sound Business Journal - May 02 2013]

Quotes

...standard of care for this stage of the disease, prior to the approval of Pixuvri in the EU," said James A Bianco, MD, president and CEO of CTI. "Pixuvri is the first medicinal product approved in the EU for the treatment of patients with aggressive non-Hodgkin B-cell lymphomas who have failed two or three prior lines of therapy, which was based on results from the only phase III study conducted in this patient population. We appreciate the Joint Committee recognizing this conundrum and providing CTI the opportunity to work with payors to arrive at an equitable price for Pixuvri, based on the cost associated with unlicensed agents or regimens currently being utilized by physicians in Germany."
Cell Therapeutics receives German Federal Joint Committee's final benefit assessment report for P ... [Published PharmaBiz - May 21 2013]
...Union where there is market access pending the completion of the reimbursement process," said James Bianco, M D , President and CEO of CTI. "Although it is early in the launch, we are pleased with the interest and receptivity of PIXUVRI by key lymphoma opinion leaders who treat patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL) and who recognize the significant unmet need that exists for these patients. In addition, our Phase III PERSIST-1 clinical trial of pacritinib, an oral, once-daily JAK2/FLT3 inhibitor, in myelofibrosis continues to progress with the opening of additional sites and growing enrollment."
Cell Therapeutics reports higher Q1 net loss, provides outlook for 2013 [Published Individual.com - May 16 2013]
...therapeutic options available for elderly patients who, after failing hypomethylating therapy, experience AML progression from MDS," said Dr Cortes. "The novel mechanism of action and observed response rate in this completed phase II study suggests that tosedostat could address this unmet medical need. We are currently conducting a phase II study investigating the combination of tosedostat with azacytidine - an HMA, or low-dose cytarabine, a standard leukaemia therapy in patients with relapsed or refractory AML and MDS - to determine if tosedostat would be safe and more effective when used in combination with these agents."
Lancet Oncology publishes tosedostat OPAL phase II study results in AML [Published PharmaBiz - Mar 05 2013]
If you require information regarding today's European corporate news please refer to the RANsquawk "EU Equity Opening News' sheet or visit www.RANsquawk.com. "
US EQUITIES OPENING HEADLINES INCLUDING: News Corp is to sell stake in New Zealand’s SKY Network ... [Published Proactiveinvestors United Kingdom RSS feed - Mar 04 2013]

More Content

All (115) | News (68) | Reports (6) | Blogs (12) | Audio/Video (0) | Fact Sheets (1) | Press Releases (28)
sort by: Date | Relevance
Form 4 CELL THERAPEUTICS INC For: May 24 Filed ... [Published Street Insider - May 24 2013]
Cell Therapeutics Inc. Files SEC Form DEF 14A, ... [Published Equities.com - May 22 2013]
Cell Therapeutics Inc. Files SEC Form DEFA14A, ... [Published Equities.com - May 22 2013]
Regenerative Medicine Markets [Published Zecco - May 22 2013]
Investors look to Lighten Up on Shares of Cell ... [Published Individual.com - May 22 2013]
Cell Therapeutics, Inc. Presents at UBS Global ... [Published Seeking Alpha - May 22 2013]
Cell Therapeutics receives German Federal Joint... [Published PharmaBiz - May 21 2013]
Gemeinsamer Bundesausschuss (G-BA) gibt Beschlu... [Published PR Newswire: Health - May 21 2013]
Germany’s G-BA Finds No Added Benefit For CTI’s... [Published The Rose Sheet - May 20 2013]
German Federal Joint Committee (G-BA) Issues Fi... [Published Stockwatch - May 20 2013]
German Federal Joint Committee (G-BA) Issues Fi... [Published PR Newswire: General Business - May 20 2013]
Lowest Return on Equity in the Biotechnology In... [Published Comtex SmarTrend - May 18 2013]
Cell Therapeutics reports higher Q1 net loss, p... [Published Individual.com - May 16 2013]
Cell Therapeutics, Inc. to Present at Upcoming ... [Published BioSpace - May 15 2013]
Cell Therapeutics to Present at Upcoming Invest... [Published Stockwatch - May 15 2013]
Cell Therapeutics to Present at Upcoming Invest... [Published Individual.com - May 15 2013]
Cell Therapeutics to Present at Upcoming Invest... [Published PR Newswire: Health - May 15 2013]
Form 4 CELL THERAPEUTICS INC For: May 09 Filed ... [Published Street Insider - May 11 2013]
Form 4 CELL THERAPEUTICS INC For: May 08 Filed ... [Published Street Insider - May 11 2013]
Deals of the Week: With Option Deal, Forest Kee... [Published The IN VIVO Blog - May 10 2013]
Cell Therapeutics Inc. Files SEC Form PRE 14A, ... [Published Equities.com - May 08 2013]
New Market Report: Sarcomas - Pipeline Review, ... [Published Live-PR.com - May 05 2013]
Cell Therapeutics Management Discusses Q1 2013 ... [Published Seeking Alpha - May 04 2013]
Cell Therapeutics, Inc. Reports First Quarter 2... [Published BioSpace - May 03 2013]
Cell Therapeutics' loss widens as it begins sel... [Published Puget Sound Business Journal - May 02 2013]
Cell Therapeutics Reports First Quarter 2013 Fi... [Published KWQC - May 02 2013]
8-K - CELL THERAPEUTICS INC (0000891293) (Filer) [Published SEC Filings - May 02 2013]
Investors Alert: Sonus Networks, Inc.(NASDAQ:SO... [Published SBWire - May 01 2013]
8-K - CELL THERAPEUTICS INC (0000891293) (Filer) [Published SEC Filings - Apr 30 2013]
New market study, "Sarcomas - Pipeline Review, ... [Published Live-PR.com - Apr 27 2013]
1 2 3 4
In Focus
  •  
James Bianco, Elliott Ave, Ed Bell, [more]
  •  
Roth Capital Partners, Dendreon Corp, ACADIA Pharmaceuticals Inc, [more]
  •  
US Securities and Exchange Commission, IQWiG, National Hockey League, [more]
  •  
8-k, myelofibrosis, Biotechnology, [more]
  •  
Pixuvri, S&P 500, Microsoft Lync, [more]
  •  
Seattle, Washington DC, Milan, [more]
  •  
United States, Germany, India, [more]
  •  
Diseases, Narcotics, Medication, [more]
  •  
Construction, Telecom, Utilities, [more]
SEC Filings, PR Newswire: Health, Stockwatch, [more]
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Deals of the Week: With Option Deal, Forest Kee... [Published The IN VIVO Blog - May 10 2013]
It’s an optimistic time for pharma dealmakers, with the Dow and the Nasdaq Biotechnology Index climbing, buyers sitting on big piles of cash, and the IPO window as wide-open as it’s been in years. But for smaller companies that have long lamented that ...
Does Celgene Support All-Time Highs? [Published Wall St. Cheat Sheet - Apr 12 2013]
With shares of  Celgene  ( NASDAQ:CELG )   trading around $123, is CELG an OUTPERFORM, WAIT AND SEE or STAY AWAY? Let’s analyze the stock with the relevant sections of our  CHEAT SHEET investing framework : T = Trends for a Stock’s Movement Celgene is ...
NICE seeks views on draft guidance for non-Hodg... [Published NICE | National Institute for Health and Clinic ... - Apr 11 2013]
A treatment for a type of non-Hodgkin's lymphoma is not recommended for NHS use in draft NICE guidance. An independent committee concluded there was insufficient evidence to show that pixantrone (Pixuvri, Cell Therapeutics) is more effective than current ...
Uneasy Lies The Head That Wears a Financings of... [Published The IN VIVO Blog - Apr 05 2013]
Compared to other types of financing, royalty-based deals in the biopharma world are rare. That’s because a company needs products with future revenue to parlay into a near-term lump sum, and the relative few companies that have such products often ...
Hot Stocks: FreeSeas, Cell Therapeutics, Excel ... [Published MaritimeSecurity.Asia - Mar 29 2013]
Houston, TX – March 28, 2013 – (MESHPRESS) – H oleinonestocks.net , an investor research portal specializing in several sectors including biotech and healthcare and tech stocks on the U.S. market, issues news updates on the following stock:- FreeSeas ...
1 2 3

Press Releases

sort by: Date | Relevance
Gemeinsamer Bundesausschuss (G-BA) gibt Beschlu... [Published PR Newswire: Health - May 21 2013]
German Federal Joint Committee (G-BA) Issues Fi... [Published PR Newswire: General Business - May 20 2013]
Cell Therapeutics to Present at Upcoming Invest... [Published PR Newswire: Health - May 15 2013]
Cell Therapeutics to Report First Quarter Finan... [Published PR Newswire: Financial Services - Apr 24 2013]
Research and Markets: Mantle Cell Lymphoma - Pi... [Published Business Wire - Apr 18 2013]
1 2 3 4 5 6
About
Silobreaker
Press Room
Products
Online Service
On-Premises Software
Contact Us
Sales
Support
Legal
Terms of Use
Privacy Policy


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2013 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.